Shares of Verona Pharma Plc (LON:VRP) opened at 3.40 on Monday. The firm’s market cap is GBX 87.23 billion. The firm’s 50-day moving average price is GBX 3.20 and its 200 day moving average price is GBX 3.26. Verona Pharma Plc has a one year low of GBX 2.17 and a one year high of GBX 5.25.
In other Verona Pharma Plc news, insider Jan-Anders Karlsson,Sven purchased 600,000 shares of the company’s stock in a transaction on Tuesday, August 9th. The shares were purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £18,000 ($23,495.63).
Verona Pharma Plc Company Profile
Verona Pharma plc is a specialist pharma company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its lead drug, RPL554, a Phosphodiesterase 3 (PDE3)/PDE4 inhibitor with both bronchodilator and anti-inflammatory activities, is in Phase II trials as a nebulized treatment for acute exacerbations of COPD in a hospital setting.
Receive News & Ratings for Verona Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.